Navigation Links
Treating diabetes during pregnancy can break link to childhood obesity
Date:8/27/2007

igator at CHR Northwest and Hawaii, and the lead author of the study. "The key finding here is that the risk of overweight and obese children rises in step with higher levels of blood sugar during pregnancy. The good news for pregnant women is that by treating gestational diabetes, your children's risk of becoming overweight or obese drops considerably."

"My advice to pregnant women is three-fold: Discuss gestational diabetes screening with your doctor, usually between weeks 24 and 28 of pregnancy; if you have gestational diabetes, work with your physician to treat it, and stick with the treatment during your pregnancy. It's the best thing you can do to reduce your child's risk of obesity," said Dr. Hillier.

Funded by a grant from the American Diabetes Association, the study was made possible by Kaiser Permanente's interlinked, computerized databases. As the nation's largest and oldest integrated care delivery system, Kaiser Permanente researchers can anonymously review patient records dating back many years and look for connections with the patient's family members and other aspects of the members health.

The women in the study were screened during pregnancy for blood sugar level and gestational diabetes. The women's children were measured for weight between the ages of 5 and 7 the so-called "adiposity rebound" period, a strong predictor of adult obesity. The relationship between maternal blood sugar and childhood obesity was then analyzed.

Children of mothers with high levels of blood sugar who were untreated were 89 percent more likely to be overweight and 82 percent more likely to be obese by the time they were 5 to 7 years of age, compared to children whose mothers had normal blood sugar levels during pregnancy.

The obesity risk of children whose mothers had the highest blood sugar levelsand were treated for gestational diabeteswas not statistically different than children of mothers with normal blood sugar levels
'/>"/>

Contact: Danielle Cass
danielle.x.cass@kp.org
510-267-5354
Kaiser Permanente Division of Research
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gene Therapy shows promise in treating Hemophilia
2. Treating Depression In Children Could Lead To Poor Bone Development
3. Treating Epilepsy With Surgery
4. Treating Autism More Effectively
5. Stem Cell Therapy Effective For Treating Heart Attacks
6. Treating Leukemia With Natural Cells
7. Treating eye pain eases migraine
8. Treating wounds without stitches
9. Treating varicose veins
10. Treating acne with laser
11. Ketoconazole 2% more effective in treating Seborrheic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 1Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 2Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 3Herley Industries Inc Reports Third Quarter Earnings 48677 1Herley Industries Inc Reports Third Quarter Earnings 48677 2Herley Industries Inc Reports Third Quarter Earnings 48677 3Herley Industries Inc Reports Third Quarter Earnings 48677 4Herley Industries Inc Reports Third Quarter Earnings 48677 5Herley Industries Inc Reports Third Quarter Earnings 48677 6Herley Industries Inc Reports Third Quarter Earnings 48677 7Herley Industries Inc Reports Third Quarter Earnings 48677 8Herley Industries Inc Reports Third Quarter Earnings 48677 9Herley Industries Inc Reports Third Quarter Earnings 48677 10Herley Industries Inc Reports Third Quarter Earnings 48677 11Herley Industries Inc Reports Third Quarter Earnings 48677 12Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 1Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 2